Pliant Therapeutics: An Activist On Deck
Source: SeekingAlpha
2025-04-03 12:22:51 ET
Summary
- Pliant Therapeutics suffered a major setback with its lead drug candidate, causing its stock to plummet well below its cash value.
- Activist investor Kevin Tang has acquired a significant stake in PLRX, aiming to capitalize on the company's large cash reserves.
- Tang's history of acquiring biotechs at a discount suggests a potential profitable takeover of PLRX, despite management's defensive "poison pill" strategy.
- The substantial gap between PLRX's current share price and its cash balance presents a compelling investment opportunity, with Tang likely to make an acquisition offer soon.
...
Read the full article on Seeking Alpha
For further details see:
Pliant Therapeutics: An Activist On Deck
Pliant Therapeutics Inc.
NASDAQ: PLRX
PLRX Trading
-1.82% G/L:
$1.345 Last:
366,040 Volume:
$1.41 Open:
PLRX Latest News
March 11, 2026 04:05:00 pm
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
February 23, 2026 08:00:00 am
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
PLRX Stock Data
$72,817,521
56,533,434
3.63%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
